
Please try another search
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Ming-Feng Hou | - | 2021 | Director |
Ming-Daw Chang | - | - | Independent Director |
Zhangyao Xu | - | - | Chairman |
Wen-Hung Hsu | 58 | - | Representative Director |
Ming-Shiang Wu | - | - | Representative Director |
Jan-Yau Hsu | - | 2025 | Director |
Pau-Chu Lo | - | 2025 | Independent Director |
Wen-Ta Chiu | - | 2025 | Independent Director |
Chien-Huang Lin | - | 2021 | Independent Director |
Rui-Wen Wu | - | 2018 | Representative Director |
Yi-Hui Lin | - | 2018 | Representative Director |
Chih-Li Wang | - | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review